Recently, we showed that ChA at a low dose of 0.75 mg/kg (given i.p. three times a week) efficiently reduced tumour growth and decreased tumour angiogenesis in vivo16, 17, 18, supporting the potential of ChA as cancer therapeutics. The gene discussed is TCFL5; the disease is neoplasm.